Global Oxytocic Pharmaceuticals Market
Global Oxytocic Pharmaceuticals Market

Oxytocic Pharmaceuticals Comprehensive Study by Route of Administration (Intramuscular, Intravenous Injection/Infusion), Indication (Abortion Induced Incomplete, Inevitable Abortion, Postpartum Hemorrhage, Labor Induction, Labor Arrest), Source of Origin (Natural Oxytocin (Animal Pituitary Extract), Synthetic Oxytocin Derivative), End User (Hospitals, Maternity Clinics, Others) Players and Region - Global Market Outlook to 2025

Oxytocic Pharmaceuticals Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Dec 2020 Edition 226 Pages 211 Tables & Figures
Sample Report Speak with Analyst Request Discount
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Oxytocic Pharmaceuticals Market?

Oxytocic drugs are used at the end of pregnancy, during labor pain, and post-delivery which induce to take a selective action on the contraction of smooth musculature of the uterus. Oxytocic drugs are used in various fields of obstetrics such as induction of labor, contraction stress test, treatment of labor arrest, management of labor, and the treatment of uterine atony and postpartum hemorrhage. The drug is also used to abort the fetus in case of miscarriage. This has led to significant growth of the global oxytocic pharmaceuticals market in the forecast period.

The market study is being classified and major geographies with country level break-up.

Fresenius Kabi AG (Germany), Baxter Healthcare Corporation (United States), Pfizer Inc. (United States), Ferring Pharmaceuticals (Switzerland), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. ( Israel), APP Pharmaceuticals, LLC (United States), LBS Labs (Belgium) and JHP Pharmaceuticals, LLC (United States) are some of the key players profiled in the study.

Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Oxytocic Pharmaceuticals market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Oxytocic Pharmaceuticals market by Type, Application and Region.

On the basis of geography, the market of Oxytocic Pharmaceuticals has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Growing Childbirth using Labor Induction
  • Increasing Cases of Pregnancy-related Complications Emerging in Developing Nations

Market Trend
  • Growing Expansion of the Health Care and Pharmaceutical Industries in Developing Countries

Restraints
  • Availability of Alternative Drugs

Opportunities
  • Rising Focus of Achieving Mortality Ratio of Less than 70 per 100,000 Live Births in Under-Resourced Regions
  • Growing Research and Development in Use of Oxytocin at Lower Doses

Challenges
  • Quality Issues Associated with Oxytocin Preparations


Market Leaders and some development strategies
On 3rd July 2019, Dr. Reddy’s Laboratories has launched Carboprost Tromethamine Injection USP, 250mcg/mL (1mL), a generic version of Hemabate (Pfizer).
On 31st May 2018, Granules Pharmaceuticals, Inc., the wholly-owned subsidiary of Granules India Ltd. partnered with West-Ward Pharmaceuticals Corp., a wholly-owned subsidiary of Hikma Pharmaceuticals PLC, to launch the generic version of Methylergonovine Maleate Tablets, USP, 0.2mg, the generic equivalent to Methergine.


Key Target Audience
Oxytocic Pharmaceuticals Manufacturers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Route of Administration
  • Intramuscular
  • Intravenous Injection/Infusion

By Indication
  • Abortion Induced Incomplete
  • Inevitable Abortion
  • Postpartum Hemorrhage
  • Labor Induction
  • Labor Arrest

By Source of Origin
  • Natural Oxytocin (Animal Pituitary Extract)
  • Synthetic Oxytocin Derivative

By End User
  • Hospitals
  • Maternity Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Childbirth using Labor Induction
      • 3.2.2. Increasing Cases of Pregnancy-related Complications Emerging in Developing Nations
    • 3.3. Market Challenges
      • 3.3.1. Quality Issues Associated with Oxytocin Preparations
    • 3.4. Market Trends
      • 3.4.1. Growing Expansion of the Health Care and Pharmaceutical Industries in Developing Countries
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Oxytocic Pharmaceuticals, by Route of Administration, Indication, Source of Origin, End User and Region (value, volume and price ) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Oxytocic Pharmaceuticals (Value)
      • 5.2.1. Global Oxytocic Pharmaceuticals by: Route of Administration (Value)
        • 5.2.1.1. Intramuscular
        • 5.2.1.2. Intravenous Injection/Infusion
      • 5.2.2. Global Oxytocic Pharmaceuticals by: Indication (Value)
        • 5.2.2.1. Abortion Induced Incomplete
        • 5.2.2.2. Inevitable Abortion
        • 5.2.2.3. Postpartum Hemorrhage
        • 5.2.2.4. Labor Induction
        • 5.2.2.5. Labor Arrest
      • 5.2.3. Global Oxytocic Pharmaceuticals by: Source of Origin (Value)
        • 5.2.3.1. Natural Oxytocin (Animal Pituitary Extract)
        • 5.2.3.2. Synthetic Oxytocin Derivative
      • 5.2.4. Global Oxytocic Pharmaceuticals by: End User (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Maternity Clinics
        • 5.2.4.3. Others
      • 5.2.5. Global Oxytocic Pharmaceuticals Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Oxytocic Pharmaceuticals (Volume)
      • 5.3.1. Global Oxytocic Pharmaceuticals by: Route of Administration (Volume)
        • 5.3.1.1. Intramuscular
        • 5.3.1.2. Intravenous Injection/Infusion
      • 5.3.2. Global Oxytocic Pharmaceuticals by: Indication (Volume)
        • 5.3.2.1. Abortion Induced Incomplete
        • 5.3.2.2. Inevitable Abortion
        • 5.3.2.3. Postpartum Hemorrhage
        • 5.3.2.4. Labor Induction
        • 5.3.2.5. Labor Arrest
      • 5.3.3. Global Oxytocic Pharmaceuticals by: Source of Origin (Volume)
        • 5.3.3.1. Natural Oxytocin (Animal Pituitary Extract)
        • 5.3.3.2. Synthetic Oxytocin Derivative
      • 5.3.4. Global Oxytocic Pharmaceuticals by: End User (Volume)
        • 5.3.4.1. Hospitals
        • 5.3.4.2. Maternity Clinics
        • 5.3.4.3. Others
      • 5.3.5. Global Oxytocic Pharmaceuticals Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Oxytocic Pharmaceuticals (Price)
  • 6. Oxytocic Pharmaceuticals: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Fresenius Kabi AG (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Baxter Healthcare Corporation (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Ferring Pharmaceuticals (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Teva Pharmaceutical Industries Ltd. ( Israel)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. APP Pharmaceuticals, LLC (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. LBS Labs (Belgium)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. JHP Pharmaceuticals, LLC (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Oxytocic Pharmaceuticals Sale, by Route of Administration, Indication, Source of Origin, End User and Region (value, volume and price ) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Oxytocic Pharmaceuticals (Value)
      • 7.2.1. Global Oxytocic Pharmaceuticals by: Route of Administration (Value)
        • 7.2.1.1. Intramuscular
        • 7.2.1.2. Intravenous Injection/Infusion
      • 7.2.2. Global Oxytocic Pharmaceuticals by: Indication (Value)
        • 7.2.2.1. Abortion Induced Incomplete
        • 7.2.2.2. Inevitable Abortion
        • 7.2.2.3. Postpartum Hemorrhage
        • 7.2.2.4. Labor Induction
        • 7.2.2.5. Labor Arrest
      • 7.2.3. Global Oxytocic Pharmaceuticals by: Source of Origin (Value)
        • 7.2.3.1. Natural Oxytocin (Animal Pituitary Extract)
        • 7.2.3.2. Synthetic Oxytocin Derivative
      • 7.2.4. Global Oxytocic Pharmaceuticals by: End User (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Maternity Clinics
        • 7.2.4.3. Others
      • 7.2.5. Global Oxytocic Pharmaceuticals Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Oxytocic Pharmaceuticals (Volume)
      • 7.3.1. Global Oxytocic Pharmaceuticals by: Route of Administration (Volume)
        • 7.3.1.1. Intramuscular
        • 7.3.1.2. Intravenous Injection/Infusion
      • 7.3.2. Global Oxytocic Pharmaceuticals by: Indication (Volume)
        • 7.3.2.1. Abortion Induced Incomplete
        • 7.3.2.2. Inevitable Abortion
        • 7.3.2.3. Postpartum Hemorrhage
        • 7.3.2.4. Labor Induction
        • 7.3.2.5. Labor Arrest
      • 7.3.3. Global Oxytocic Pharmaceuticals by: Source of Origin (Volume)
        • 7.3.3.1. Natural Oxytocin (Animal Pituitary Extract)
        • 7.3.3.2. Synthetic Oxytocin Derivative
      • 7.3.4. Global Oxytocic Pharmaceuticals by: End User (Volume)
        • 7.3.4.1. Hospitals
        • 7.3.4.2. Maternity Clinics
        • 7.3.4.3. Others
      • 7.3.5. Global Oxytocic Pharmaceuticals Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Oxytocic Pharmaceuticals (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Oxytocic Pharmaceuticals: by Route of Administration(USD Million)
  • Table 2. Oxytocic Pharmaceuticals Intramuscular , by Region USD Million (2014-2019)
  • Table 3. Oxytocic Pharmaceuticals Intravenous Injection/Infusion , by Region USD Million (2014-2019)
  • Table 4. Oxytocic Pharmaceuticals: by Indication(USD Million)
  • Table 5. Oxytocic Pharmaceuticals Abortion Induced Incomplete , by Region USD Million (2014-2019)
  • Table 6. Oxytocic Pharmaceuticals Inevitable Abortion , by Region USD Million (2014-2019)
  • Table 7. Oxytocic Pharmaceuticals Postpartum Hemorrhage , by Region USD Million (2014-2019)
  • Table 8. Oxytocic Pharmaceuticals Labor Induction , by Region USD Million (2014-2019)
  • Table 9. Oxytocic Pharmaceuticals Labor Arrest , by Region USD Million (2014-2019)
  • Table 10. Oxytocic Pharmaceuticals: by Source of Origin(USD Million)
  • Table 11. Oxytocic Pharmaceuticals Natural Oxytocin (Animal Pituitary Extract) , by Region USD Million (2014-2019)
  • Table 12. Oxytocic Pharmaceuticals Synthetic Oxytocin Derivative , by Region USD Million (2014-2019)
  • Table 13. Oxytocic Pharmaceuticals: by End User(USD Million)
  • Table 14. Oxytocic Pharmaceuticals Hospitals , by Region USD Million (2014-2019)
  • Table 15. Oxytocic Pharmaceuticals Maternity Clinics , by Region USD Million (2014-2019)
  • Table 16. Oxytocic Pharmaceuticals Others , by Region USD Million (2014-2019)
  • Table 17. South America Oxytocic Pharmaceuticals, by Country USD Million (2014-2019)
  • Table 18. South America Oxytocic Pharmaceuticals, by Route of Administration USD Million (2014-2019)
  • Table 19. South America Oxytocic Pharmaceuticals, by Indication USD Million (2014-2019)
  • Table 20. South America Oxytocic Pharmaceuticals, by Source of Origin USD Million (2014-2019)
  • Table 21. South America Oxytocic Pharmaceuticals, by End User USD Million (2014-2019)
  • Table 22. Brazil Oxytocic Pharmaceuticals, by Route of Administration USD Million (2014-2019)
  • Table 23. Brazil Oxytocic Pharmaceuticals, by Indication USD Million (2014-2019)
  • Table 24. Brazil Oxytocic Pharmaceuticals, by Source of Origin USD Million (2014-2019)
  • Table 25. Brazil Oxytocic Pharmaceuticals, by End User USD Million (2014-2019)
  • Table 26. Argentina Oxytocic Pharmaceuticals, by Route of Administration USD Million (2014-2019)
  • Table 27. Argentina Oxytocic Pharmaceuticals, by Indication USD Million (2014-2019)
  • Table 28. Argentina Oxytocic Pharmaceuticals, by Source of Origin USD Million (2014-2019)
  • Table 29. Argentina Oxytocic Pharmaceuticals, by End User USD Million (2014-2019)
  • Table 30. Rest of South America Oxytocic Pharmaceuticals, by Route of Administration USD Million (2014-2019)
  • Table 31. Rest of South America Oxytocic Pharmaceuticals, by Indication USD Million (2014-2019)
  • Table 32. Rest of South America Oxytocic Pharmaceuticals, by Source of Origin USD Million (2014-2019)
  • Table 33. Rest of South America Oxytocic Pharmaceuticals, by End User USD Million (2014-2019)
  • Table 34. Asia Pacific Oxytocic Pharmaceuticals, by Country USD Million (2014-2019)
  • Table 35. Asia Pacific Oxytocic Pharmaceuticals, by Route of Administration USD Million (2014-2019)
  • Table 36. Asia Pacific Oxytocic Pharmaceuticals, by Indication USD Million (2014-2019)
  • Table 37. Asia Pacific Oxytocic Pharmaceuticals, by Source of Origin USD Million (2014-2019)
  • Table 38. Asia Pacific Oxytocic Pharmaceuticals, by End User USD Million (2014-2019)
  • Table 39. China Oxytocic Pharmaceuticals, by Route of Administration USD Million (2014-2019)
  • Table 40. China Oxytocic Pharmaceuticals, by Indication USD Million (2014-2019)
  • Table 41. China Oxytocic Pharmaceuticals, by Source of Origin USD Million (2014-2019)
  • Table 42. China Oxytocic Pharmaceuticals, by End User USD Million (2014-2019)
  • Table 43. Japan Oxytocic Pharmaceuticals, by Route of Administration USD Million (2014-2019)
  • Table 44. Japan Oxytocic Pharmaceuticals, by Indication USD Million (2014-2019)
  • Table 45. Japan Oxytocic Pharmaceuticals, by Source of Origin USD Million (2014-2019)
  • Table 46. Japan Oxytocic Pharmaceuticals, by End User USD Million (2014-2019)
  • Table 47. India Oxytocic Pharmaceuticals, by Route of Administration USD Million (2014-2019)
  • Table 48. India Oxytocic Pharmaceuticals, by Indication USD Million (2014-2019)
  • Table 49. India Oxytocic Pharmaceuticals, by Source of Origin USD Million (2014-2019)
  • Table 50. India Oxytocic Pharmaceuticals, by End User USD Million (2014-2019)
  • Table 51. South Korea Oxytocic Pharmaceuticals, by Route of Administration USD Million (2014-2019)
  • Table 52. South Korea Oxytocic Pharmaceuticals, by Indication USD Million (2014-2019)
  • Table 53. South Korea Oxytocic Pharmaceuticals, by Source of Origin USD Million (2014-2019)
  • Table 54. South Korea Oxytocic Pharmaceuticals, by End User USD Million (2014-2019)
  • Table 55. Taiwan Oxytocic Pharmaceuticals, by Route of Administration USD Million (2014-2019)
  • Table 56. Taiwan Oxytocic Pharmaceuticals, by Indication USD Million (2014-2019)
  • Table 57. Taiwan Oxytocic Pharmaceuticals, by Source of Origin USD Million (2014-2019)
  • Table 58. Taiwan Oxytocic Pharmaceuticals, by End User USD Million (2014-2019)
  • Table 59. Australia Oxytocic Pharmaceuticals, by Route of Administration USD Million (2014-2019)
  • Table 60. Australia Oxytocic Pharmaceuticals, by Indication USD Million (2014-2019)
  • Table 61. Australia Oxytocic Pharmaceuticals, by Source of Origin USD Million (2014-2019)
  • Table 62. Australia Oxytocic Pharmaceuticals, by End User USD Million (2014-2019)
  • Table 63. Rest of Asia-Pacific Oxytocic Pharmaceuticals, by Route of Administration USD Million (2014-2019)
  • Table 64. Rest of Asia-Pacific Oxytocic Pharmaceuticals, by Indication USD Million (2014-2019)
  • Table 65. Rest of Asia-Pacific Oxytocic Pharmaceuticals, by Source of Origin USD Million (2014-2019)
  • Table 66. Rest of Asia-Pacific Oxytocic Pharmaceuticals, by End User USD Million (2014-2019)
  • Table 67. Europe Oxytocic Pharmaceuticals, by Country USD Million (2014-2019)
  • Table 68. Europe Oxytocic Pharmaceuticals, by Route of Administration USD Million (2014-2019)
  • Table 69. Europe Oxytocic Pharmaceuticals, by Indication USD Million (2014-2019)
  • Table 70. Europe Oxytocic Pharmaceuticals, by Source of Origin USD Million (2014-2019)
  • Table 71. Europe Oxytocic Pharmaceuticals, by End User USD Million (2014-2019)
  • Table 72. Germany Oxytocic Pharmaceuticals, by Route of Administration USD Million (2014-2019)
  • Table 73. Germany Oxytocic Pharmaceuticals, by Indication USD Million (2014-2019)
  • Table 74. Germany Oxytocic Pharmaceuticals, by Source of Origin USD Million (2014-2019)
  • Table 75. Germany Oxytocic Pharmaceuticals, by End User USD Million (2014-2019)
  • Table 76. France Oxytocic Pharmaceuticals, by Route of Administration USD Million (2014-2019)
  • Table 77. France Oxytocic Pharmaceuticals, by Indication USD Million (2014-2019)
  • Table 78. France Oxytocic Pharmaceuticals, by Source of Origin USD Million (2014-2019)
  • Table 79. France Oxytocic Pharmaceuticals, by End User USD Million (2014-2019)
  • Table 80. Italy Oxytocic Pharmaceuticals, by Route of Administration USD Million (2014-2019)
  • Table 81. Italy Oxytocic Pharmaceuticals, by Indication USD Million (2014-2019)
  • Table 82. Italy Oxytocic Pharmaceuticals, by Source of Origin USD Million (2014-2019)
  • Table 83. Italy Oxytocic Pharmaceuticals, by End User USD Million (2014-2019)
  • Table 84. United Kingdom Oxytocic Pharmaceuticals, by Route of Administration USD Million (2014-2019)
  • Table 85. United Kingdom Oxytocic Pharmaceuticals, by Indication USD Million (2014-2019)
  • Table 86. United Kingdom Oxytocic Pharmaceuticals, by Source of Origin USD Million (2014-2019)
  • Table 87. United Kingdom Oxytocic Pharmaceuticals, by End User USD Million (2014-2019)
  • Table 88. Netherlands Oxytocic Pharmaceuticals, by Route of Administration USD Million (2014-2019)
  • Table 89. Netherlands Oxytocic Pharmaceuticals, by Indication USD Million (2014-2019)
  • Table 90. Netherlands Oxytocic Pharmaceuticals, by Source of Origin USD Million (2014-2019)
  • Table 91. Netherlands Oxytocic Pharmaceuticals, by End User USD Million (2014-2019)
  • Table 92. Rest of Europe Oxytocic Pharmaceuticals, by Route of Administration USD Million (2014-2019)
  • Table 93. Rest of Europe Oxytocic Pharmaceuticals, by Indication USD Million (2014-2019)
  • Table 94. Rest of Europe Oxytocic Pharmaceuticals, by Source of Origin USD Million (2014-2019)
  • Table 95. Rest of Europe Oxytocic Pharmaceuticals, by End User USD Million (2014-2019)
  • Table 96. MEA Oxytocic Pharmaceuticals, by Country USD Million (2014-2019)
  • Table 97. MEA Oxytocic Pharmaceuticals, by Route of Administration USD Million (2014-2019)
  • Table 98. MEA Oxytocic Pharmaceuticals, by Indication USD Million (2014-2019)
  • Table 99. MEA Oxytocic Pharmaceuticals, by Source of Origin USD Million (2014-2019)
  • Table 100. MEA Oxytocic Pharmaceuticals, by End User USD Million (2014-2019)
  • Table 101. Middle East Oxytocic Pharmaceuticals, by Route of Administration USD Million (2014-2019)
  • Table 102. Middle East Oxytocic Pharmaceuticals, by Indication USD Million (2014-2019)
  • Table 103. Middle East Oxytocic Pharmaceuticals, by Source of Origin USD Million (2014-2019)
  • Table 104. Middle East Oxytocic Pharmaceuticals, by End User USD Million (2014-2019)
  • Table 105. Africa Oxytocic Pharmaceuticals, by Route of Administration USD Million (2014-2019)
  • Table 106. Africa Oxytocic Pharmaceuticals, by Indication USD Million (2014-2019)
  • Table 107. Africa Oxytocic Pharmaceuticals, by Source of Origin USD Million (2014-2019)
  • Table 108. Africa Oxytocic Pharmaceuticals, by End User USD Million (2014-2019)
  • Table 109. North America Oxytocic Pharmaceuticals, by Country USD Million (2014-2019)
  • Table 110. North America Oxytocic Pharmaceuticals, by Route of Administration USD Million (2014-2019)
  • Table 111. North America Oxytocic Pharmaceuticals, by Indication USD Million (2014-2019)
  • Table 112. North America Oxytocic Pharmaceuticals, by Source of Origin USD Million (2014-2019)
  • Table 113. North America Oxytocic Pharmaceuticals, by End User USD Million (2014-2019)
  • Table 114. United States Oxytocic Pharmaceuticals, by Route of Administration USD Million (2014-2019)
  • Table 115. United States Oxytocic Pharmaceuticals, by Indication USD Million (2014-2019)
  • Table 116. United States Oxytocic Pharmaceuticals, by Source of Origin USD Million (2014-2019)
  • Table 117. United States Oxytocic Pharmaceuticals, by End User USD Million (2014-2019)
  • Table 118. Canada Oxytocic Pharmaceuticals, by Route of Administration USD Million (2014-2019)
  • Table 119. Canada Oxytocic Pharmaceuticals, by Indication USD Million (2014-2019)
  • Table 120. Canada Oxytocic Pharmaceuticals, by Source of Origin USD Million (2014-2019)
  • Table 121. Canada Oxytocic Pharmaceuticals, by End User USD Million (2014-2019)
  • Table 122. Mexico Oxytocic Pharmaceuticals, by Route of Administration USD Million (2014-2019)
  • Table 123. Mexico Oxytocic Pharmaceuticals, by Indication USD Million (2014-2019)
  • Table 124. Mexico Oxytocic Pharmaceuticals, by Source of Origin USD Million (2014-2019)
  • Table 125. Mexico Oxytocic Pharmaceuticals, by End User USD Million (2014-2019)
  • Table 126. Oxytocic Pharmaceuticals Sales: by Route of Administration(Litres)
  • Table 127. Oxytocic Pharmaceuticals Sales Intramuscular , by Region Litres (2014-2019)
  • Table 128. Oxytocic Pharmaceuticals Sales Intravenous Injection/Infusion , by Region Litres (2014-2019)
  • Table 129. Oxytocic Pharmaceuticals Sales: by Indication(Litres)
  • Table 130. Oxytocic Pharmaceuticals Sales Abortion Induced Incomplete , by Region Litres (2014-2019)
  • Table 131. Oxytocic Pharmaceuticals Sales Inevitable Abortion , by Region Litres (2014-2019)
  • Table 132. Oxytocic Pharmaceuticals Sales Postpartum Hemorrhage , by Region Litres (2014-2019)
  • Table 133. Oxytocic Pharmaceuticals Sales Labor Induction , by Region Litres (2014-2019)
  • Table 134. Oxytocic Pharmaceuticals Sales Labor Arrest , by Region Litres (2014-2019)
  • Table 135. Oxytocic Pharmaceuticals Sales: by Source of Origin(Litres)
  • Table 136. Oxytocic Pharmaceuticals Sales Natural Oxytocin (Animal Pituitary Extract) , by Region Litres (2014-2019)
  • Table 137. Oxytocic Pharmaceuticals Sales Synthetic Oxytocin Derivative , by Region Litres (2014-2019)
  • Table 138. Oxytocic Pharmaceuticals Sales: by End User(Litres)
  • Table 139. Oxytocic Pharmaceuticals Sales Hospitals , by Region Litres (2014-2019)
  • Table 140. Oxytocic Pharmaceuticals Sales Maternity Clinics , by Region Litres (2014-2019)
  • Table 141. Oxytocic Pharmaceuticals Sales Others , by Region Litres (2014-2019)
  • Table 142. South America Oxytocic Pharmaceuticals Sales, by Country Litres (2014-2019)
  • Table 143. South America Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2014-2019)
  • Table 144. South America Oxytocic Pharmaceuticals Sales, by Indication Litres (2014-2019)
  • Table 145. South America Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2014-2019)
  • Table 146. South America Oxytocic Pharmaceuticals Sales, by End User Litres (2014-2019)
  • Table 147. Brazil Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2014-2019)
  • Table 148. Brazil Oxytocic Pharmaceuticals Sales, by Indication Litres (2014-2019)
  • Table 149. Brazil Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2014-2019)
  • Table 150. Brazil Oxytocic Pharmaceuticals Sales, by End User Litres (2014-2019)
  • Table 151. Argentina Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2014-2019)
  • Table 152. Argentina Oxytocic Pharmaceuticals Sales, by Indication Litres (2014-2019)
  • Table 153. Argentina Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2014-2019)
  • Table 154. Argentina Oxytocic Pharmaceuticals Sales, by End User Litres (2014-2019)
  • Table 155. Rest of South America Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2014-2019)
  • Table 156. Rest of South America Oxytocic Pharmaceuticals Sales, by Indication Litres (2014-2019)
  • Table 157. Rest of South America Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2014-2019)
  • Table 158. Rest of South America Oxytocic Pharmaceuticals Sales, by End User Litres (2014-2019)
  • Table 159. Asia Pacific Oxytocic Pharmaceuticals Sales, by Country Litres (2014-2019)
  • Table 160. Asia Pacific Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2014-2019)
  • Table 161. Asia Pacific Oxytocic Pharmaceuticals Sales, by Indication Litres (2014-2019)
  • Table 162. Asia Pacific Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2014-2019)
  • Table 163. Asia Pacific Oxytocic Pharmaceuticals Sales, by End User Litres (2014-2019)
  • Table 164. China Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2014-2019)
  • Table 165. China Oxytocic Pharmaceuticals Sales, by Indication Litres (2014-2019)
  • Table 166. China Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2014-2019)
  • Table 167. China Oxytocic Pharmaceuticals Sales, by End User Litres (2014-2019)
  • Table 168. Japan Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2014-2019)
  • Table 169. Japan Oxytocic Pharmaceuticals Sales, by Indication Litres (2014-2019)
  • Table 170. Japan Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2014-2019)
  • Table 171. Japan Oxytocic Pharmaceuticals Sales, by End User Litres (2014-2019)
  • Table 172. India Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2014-2019)
  • Table 173. India Oxytocic Pharmaceuticals Sales, by Indication Litres (2014-2019)
  • Table 174. India Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2014-2019)
  • Table 175. India Oxytocic Pharmaceuticals Sales, by End User Litres (2014-2019)
  • Table 176. South Korea Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2014-2019)
  • Table 177. South Korea Oxytocic Pharmaceuticals Sales, by Indication Litres (2014-2019)
  • Table 178. South Korea Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2014-2019)
  • Table 179. South Korea Oxytocic Pharmaceuticals Sales, by End User Litres (2014-2019)
  • Table 180. Taiwan Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2014-2019)
  • Table 181. Taiwan Oxytocic Pharmaceuticals Sales, by Indication Litres (2014-2019)
  • Table 182. Taiwan Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2014-2019)
  • Table 183. Taiwan Oxytocic Pharmaceuticals Sales, by End User Litres (2014-2019)
  • Table 184. Australia Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2014-2019)
  • Table 185. Australia Oxytocic Pharmaceuticals Sales, by Indication Litres (2014-2019)
  • Table 186. Australia Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2014-2019)
  • Table 187. Australia Oxytocic Pharmaceuticals Sales, by End User Litres (2014-2019)
  • Table 188. Rest of Asia-Pacific Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2014-2019)
  • Table 189. Rest of Asia-Pacific Oxytocic Pharmaceuticals Sales, by Indication Litres (2014-2019)
  • Table 190. Rest of Asia-Pacific Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2014-2019)
  • Table 191. Rest of Asia-Pacific Oxytocic Pharmaceuticals Sales, by End User Litres (2014-2019)
  • Table 192. Europe Oxytocic Pharmaceuticals Sales, by Country Litres (2014-2019)
  • Table 193. Europe Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2014-2019)
  • Table 194. Europe Oxytocic Pharmaceuticals Sales, by Indication Litres (2014-2019)
  • Table 195. Europe Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2014-2019)
  • Table 196. Europe Oxytocic Pharmaceuticals Sales, by End User Litres (2014-2019)
  • Table 197. Germany Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2014-2019)
  • Table 198. Germany Oxytocic Pharmaceuticals Sales, by Indication Litres (2014-2019)
  • Table 199. Germany Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2014-2019)
  • Table 200. Germany Oxytocic Pharmaceuticals Sales, by End User Litres (2014-2019)
  • Table 201. France Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2014-2019)
  • Table 202. France Oxytocic Pharmaceuticals Sales, by Indication Litres (2014-2019)
  • Table 203. France Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2014-2019)
  • Table 204. France Oxytocic Pharmaceuticals Sales, by End User Litres (2014-2019)
  • Table 205. Italy Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2014-2019)
  • Table 206. Italy Oxytocic Pharmaceuticals Sales, by Indication Litres (2014-2019)
  • Table 207. Italy Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2014-2019)
  • Table 208. Italy Oxytocic Pharmaceuticals Sales, by End User Litres (2014-2019)
  • Table 209. United Kingdom Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2014-2019)
  • Table 210. United Kingdom Oxytocic Pharmaceuticals Sales, by Indication Litres (2014-2019)
  • Table 211. United Kingdom Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2014-2019)
  • Table 212. United Kingdom Oxytocic Pharmaceuticals Sales, by End User Litres (2014-2019)
  • Table 213. Netherlands Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2014-2019)
  • Table 214. Netherlands Oxytocic Pharmaceuticals Sales, by Indication Litres (2014-2019)
  • Table 215. Netherlands Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2014-2019)
  • Table 216. Netherlands Oxytocic Pharmaceuticals Sales, by End User Litres (2014-2019)
  • Table 217. Rest of Europe Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2014-2019)
  • Table 218. Rest of Europe Oxytocic Pharmaceuticals Sales, by Indication Litres (2014-2019)
  • Table 219. Rest of Europe Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2014-2019)
  • Table 220. Rest of Europe Oxytocic Pharmaceuticals Sales, by End User Litres (2014-2019)
  • Table 221. MEA Oxytocic Pharmaceuticals Sales, by Country Litres (2014-2019)
  • Table 222. MEA Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2014-2019)
  • Table 223. MEA Oxytocic Pharmaceuticals Sales, by Indication Litres (2014-2019)
  • Table 224. MEA Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2014-2019)
  • Table 225. MEA Oxytocic Pharmaceuticals Sales, by End User Litres (2014-2019)
  • Table 226. Middle East Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2014-2019)
  • Table 227. Middle East Oxytocic Pharmaceuticals Sales, by Indication Litres (2014-2019)
  • Table 228. Middle East Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2014-2019)
  • Table 229. Middle East Oxytocic Pharmaceuticals Sales, by End User Litres (2014-2019)
  • Table 230. Africa Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2014-2019)
  • Table 231. Africa Oxytocic Pharmaceuticals Sales, by Indication Litres (2014-2019)
  • Table 232. Africa Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2014-2019)
  • Table 233. Africa Oxytocic Pharmaceuticals Sales, by End User Litres (2014-2019)
  • Table 234. North America Oxytocic Pharmaceuticals Sales, by Country Litres (2014-2019)
  • Table 235. North America Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2014-2019)
  • Table 236. North America Oxytocic Pharmaceuticals Sales, by Indication Litres (2014-2019)
  • Table 237. North America Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2014-2019)
  • Table 238. North America Oxytocic Pharmaceuticals Sales, by End User Litres (2014-2019)
  • Table 239. United States Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2014-2019)
  • Table 240. United States Oxytocic Pharmaceuticals Sales, by Indication Litres (2014-2019)
  • Table 241. United States Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2014-2019)
  • Table 242. United States Oxytocic Pharmaceuticals Sales, by End User Litres (2014-2019)
  • Table 243. Canada Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2014-2019)
  • Table 244. Canada Oxytocic Pharmaceuticals Sales, by Indication Litres (2014-2019)
  • Table 245. Canada Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2014-2019)
  • Table 246. Canada Oxytocic Pharmaceuticals Sales, by End User Litres (2014-2019)
  • Table 247. Mexico Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2014-2019)
  • Table 248. Mexico Oxytocic Pharmaceuticals Sales, by Indication Litres (2014-2019)
  • Table 249. Mexico Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2014-2019)
  • Table 250. Mexico Oxytocic Pharmaceuticals Sales, by End User Litres (2014-2019)
  • Table 251. Company Basic Information, Sales Area and Its Competitors
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Oxytocic Pharmaceuticals: by Route of Administration(USD Million)
  • Table 261. Oxytocic Pharmaceuticals Intramuscular , by Region USD Million (2020-2025)
  • Table 262. Oxytocic Pharmaceuticals Intravenous Injection/Infusion , by Region USD Million (2020-2025)
  • Table 263. Oxytocic Pharmaceuticals: by Indication(USD Million)
  • Table 264. Oxytocic Pharmaceuticals Abortion Induced Incomplete , by Region USD Million (2020-2025)
  • Table 265. Oxytocic Pharmaceuticals Inevitable Abortion , by Region USD Million (2020-2025)
  • Table 266. Oxytocic Pharmaceuticals Postpartum Hemorrhage , by Region USD Million (2020-2025)
  • Table 267. Oxytocic Pharmaceuticals Labor Induction , by Region USD Million (2020-2025)
  • Table 268. Oxytocic Pharmaceuticals Labor Arrest , by Region USD Million (2020-2025)
  • Table 269. Oxytocic Pharmaceuticals: by Source of Origin(USD Million)
  • Table 270. Oxytocic Pharmaceuticals Natural Oxytocin (Animal Pituitary Extract) , by Region USD Million (2020-2025)
  • Table 271. Oxytocic Pharmaceuticals Synthetic Oxytocin Derivative , by Region USD Million (2020-2025)
  • Table 272. Oxytocic Pharmaceuticals: by End User(USD Million)
  • Table 273. Oxytocic Pharmaceuticals Hospitals , by Region USD Million (2020-2025)
  • Table 274. Oxytocic Pharmaceuticals Maternity Clinics , by Region USD Million (2020-2025)
  • Table 275. Oxytocic Pharmaceuticals Others , by Region USD Million (2020-2025)
  • Table 276. South America Oxytocic Pharmaceuticals, by Country USD Million (2020-2025)
  • Table 277. South America Oxytocic Pharmaceuticals, by Route of Administration USD Million (2020-2025)
  • Table 278. South America Oxytocic Pharmaceuticals, by Indication USD Million (2020-2025)
  • Table 279. South America Oxytocic Pharmaceuticals, by Source of Origin USD Million (2020-2025)
  • Table 280. South America Oxytocic Pharmaceuticals, by End User USD Million (2020-2025)
  • Table 281. Brazil Oxytocic Pharmaceuticals, by Route of Administration USD Million (2020-2025)
  • Table 282. Brazil Oxytocic Pharmaceuticals, by Indication USD Million (2020-2025)
  • Table 283. Brazil Oxytocic Pharmaceuticals, by Source of Origin USD Million (2020-2025)
  • Table 284. Brazil Oxytocic Pharmaceuticals, by End User USD Million (2020-2025)
  • Table 285. Argentina Oxytocic Pharmaceuticals, by Route of Administration USD Million (2020-2025)
  • Table 286. Argentina Oxytocic Pharmaceuticals, by Indication USD Million (2020-2025)
  • Table 287. Argentina Oxytocic Pharmaceuticals, by Source of Origin USD Million (2020-2025)
  • Table 288. Argentina Oxytocic Pharmaceuticals, by End User USD Million (2020-2025)
  • Table 289. Rest of South America Oxytocic Pharmaceuticals, by Route of Administration USD Million (2020-2025)
  • Table 290. Rest of South America Oxytocic Pharmaceuticals, by Indication USD Million (2020-2025)
  • Table 291. Rest of South America Oxytocic Pharmaceuticals, by Source of Origin USD Million (2020-2025)
  • Table 292. Rest of South America Oxytocic Pharmaceuticals, by End User USD Million (2020-2025)
  • Table 293. Asia Pacific Oxytocic Pharmaceuticals, by Country USD Million (2020-2025)
  • Table 294. Asia Pacific Oxytocic Pharmaceuticals, by Route of Administration USD Million (2020-2025)
  • Table 295. Asia Pacific Oxytocic Pharmaceuticals, by Indication USD Million (2020-2025)
  • Table 296. Asia Pacific Oxytocic Pharmaceuticals, by Source of Origin USD Million (2020-2025)
  • Table 297. Asia Pacific Oxytocic Pharmaceuticals, by End User USD Million (2020-2025)
  • Table 298. China Oxytocic Pharmaceuticals, by Route of Administration USD Million (2020-2025)
  • Table 299. China Oxytocic Pharmaceuticals, by Indication USD Million (2020-2025)
  • Table 300. China Oxytocic Pharmaceuticals, by Source of Origin USD Million (2020-2025)
  • Table 301. China Oxytocic Pharmaceuticals, by End User USD Million (2020-2025)
  • Table 302. Japan Oxytocic Pharmaceuticals, by Route of Administration USD Million (2020-2025)
  • Table 303. Japan Oxytocic Pharmaceuticals, by Indication USD Million (2020-2025)
  • Table 304. Japan Oxytocic Pharmaceuticals, by Source of Origin USD Million (2020-2025)
  • Table 305. Japan Oxytocic Pharmaceuticals, by End User USD Million (2020-2025)
  • Table 306. India Oxytocic Pharmaceuticals, by Route of Administration USD Million (2020-2025)
  • Table 307. India Oxytocic Pharmaceuticals, by Indication USD Million (2020-2025)
  • Table 308. India Oxytocic Pharmaceuticals, by Source of Origin USD Million (2020-2025)
  • Table 309. India Oxytocic Pharmaceuticals, by End User USD Million (2020-2025)
  • Table 310. South Korea Oxytocic Pharmaceuticals, by Route of Administration USD Million (2020-2025)
  • Table 311. South Korea Oxytocic Pharmaceuticals, by Indication USD Million (2020-2025)
  • Table 312. South Korea Oxytocic Pharmaceuticals, by Source of Origin USD Million (2020-2025)
  • Table 313. South Korea Oxytocic Pharmaceuticals, by End User USD Million (2020-2025)
  • Table 314. Taiwan Oxytocic Pharmaceuticals, by Route of Administration USD Million (2020-2025)
  • Table 315. Taiwan Oxytocic Pharmaceuticals, by Indication USD Million (2020-2025)
  • Table 316. Taiwan Oxytocic Pharmaceuticals, by Source of Origin USD Million (2020-2025)
  • Table 317. Taiwan Oxytocic Pharmaceuticals, by End User USD Million (2020-2025)
  • Table 318. Australia Oxytocic Pharmaceuticals, by Route of Administration USD Million (2020-2025)
  • Table 319. Australia Oxytocic Pharmaceuticals, by Indication USD Million (2020-2025)
  • Table 320. Australia Oxytocic Pharmaceuticals, by Source of Origin USD Million (2020-2025)
  • Table 321. Australia Oxytocic Pharmaceuticals, by End User USD Million (2020-2025)
  • Table 322. Rest of Asia-Pacific Oxytocic Pharmaceuticals, by Route of Administration USD Million (2020-2025)
  • Table 323. Rest of Asia-Pacific Oxytocic Pharmaceuticals, by Indication USD Million (2020-2025)
  • Table 324. Rest of Asia-Pacific Oxytocic Pharmaceuticals, by Source of Origin USD Million (2020-2025)
  • Table 325. Rest of Asia-Pacific Oxytocic Pharmaceuticals, by End User USD Million (2020-2025)
  • Table 326. Europe Oxytocic Pharmaceuticals, by Country USD Million (2020-2025)
  • Table 327. Europe Oxytocic Pharmaceuticals, by Route of Administration USD Million (2020-2025)
  • Table 328. Europe Oxytocic Pharmaceuticals, by Indication USD Million (2020-2025)
  • Table 329. Europe Oxytocic Pharmaceuticals, by Source of Origin USD Million (2020-2025)
  • Table 330. Europe Oxytocic Pharmaceuticals, by End User USD Million (2020-2025)
  • Table 331. Germany Oxytocic Pharmaceuticals, by Route of Administration USD Million (2020-2025)
  • Table 332. Germany Oxytocic Pharmaceuticals, by Indication USD Million (2020-2025)
  • Table 333. Germany Oxytocic Pharmaceuticals, by Source of Origin USD Million (2020-2025)
  • Table 334. Germany Oxytocic Pharmaceuticals, by End User USD Million (2020-2025)
  • Table 335. France Oxytocic Pharmaceuticals, by Route of Administration USD Million (2020-2025)
  • Table 336. France Oxytocic Pharmaceuticals, by Indication USD Million (2020-2025)
  • Table 337. France Oxytocic Pharmaceuticals, by Source of Origin USD Million (2020-2025)
  • Table 338. France Oxytocic Pharmaceuticals, by End User USD Million (2020-2025)
  • Table 339. Italy Oxytocic Pharmaceuticals, by Route of Administration USD Million (2020-2025)
  • Table 340. Italy Oxytocic Pharmaceuticals, by Indication USD Million (2020-2025)
  • Table 341. Italy Oxytocic Pharmaceuticals, by Source of Origin USD Million (2020-2025)
  • Table 342. Italy Oxytocic Pharmaceuticals, by End User USD Million (2020-2025)
  • Table 343. United Kingdom Oxytocic Pharmaceuticals, by Route of Administration USD Million (2020-2025)
  • Table 344. United Kingdom Oxytocic Pharmaceuticals, by Indication USD Million (2020-2025)
  • Table 345. United Kingdom Oxytocic Pharmaceuticals, by Source of Origin USD Million (2020-2025)
  • Table 346. United Kingdom Oxytocic Pharmaceuticals, by End User USD Million (2020-2025)
  • Table 347. Netherlands Oxytocic Pharmaceuticals, by Route of Administration USD Million (2020-2025)
  • Table 348. Netherlands Oxytocic Pharmaceuticals, by Indication USD Million (2020-2025)
  • Table 349. Netherlands Oxytocic Pharmaceuticals, by Source of Origin USD Million (2020-2025)
  • Table 350. Netherlands Oxytocic Pharmaceuticals, by End User USD Million (2020-2025)
  • Table 351. Rest of Europe Oxytocic Pharmaceuticals, by Route of Administration USD Million (2020-2025)
  • Table 352. Rest of Europe Oxytocic Pharmaceuticals, by Indication USD Million (2020-2025)
  • Table 353. Rest of Europe Oxytocic Pharmaceuticals, by Source of Origin USD Million (2020-2025)
  • Table 354. Rest of Europe Oxytocic Pharmaceuticals, by End User USD Million (2020-2025)
  • Table 355. MEA Oxytocic Pharmaceuticals, by Country USD Million (2020-2025)
  • Table 356. MEA Oxytocic Pharmaceuticals, by Route of Administration USD Million (2020-2025)
  • Table 357. MEA Oxytocic Pharmaceuticals, by Indication USD Million (2020-2025)
  • Table 358. MEA Oxytocic Pharmaceuticals, by Source of Origin USD Million (2020-2025)
  • Table 359. MEA Oxytocic Pharmaceuticals, by End User USD Million (2020-2025)
  • Table 360. Middle East Oxytocic Pharmaceuticals, by Route of Administration USD Million (2020-2025)
  • Table 361. Middle East Oxytocic Pharmaceuticals, by Indication USD Million (2020-2025)
  • Table 362. Middle East Oxytocic Pharmaceuticals, by Source of Origin USD Million (2020-2025)
  • Table 363. Middle East Oxytocic Pharmaceuticals, by End User USD Million (2020-2025)
  • Table 364. Africa Oxytocic Pharmaceuticals, by Route of Administration USD Million (2020-2025)
  • Table 365. Africa Oxytocic Pharmaceuticals, by Indication USD Million (2020-2025)
  • Table 366. Africa Oxytocic Pharmaceuticals, by Source of Origin USD Million (2020-2025)
  • Table 367. Africa Oxytocic Pharmaceuticals, by End User USD Million (2020-2025)
  • Table 368. North America Oxytocic Pharmaceuticals, by Country USD Million (2020-2025)
  • Table 369. North America Oxytocic Pharmaceuticals, by Route of Administration USD Million (2020-2025)
  • Table 370. North America Oxytocic Pharmaceuticals, by Indication USD Million (2020-2025)
  • Table 371. North America Oxytocic Pharmaceuticals, by Source of Origin USD Million (2020-2025)
  • Table 372. North America Oxytocic Pharmaceuticals, by End User USD Million (2020-2025)
  • Table 373. United States Oxytocic Pharmaceuticals, by Route of Administration USD Million (2020-2025)
  • Table 374. United States Oxytocic Pharmaceuticals, by Indication USD Million (2020-2025)
  • Table 375. United States Oxytocic Pharmaceuticals, by Source of Origin USD Million (2020-2025)
  • Table 376. United States Oxytocic Pharmaceuticals, by End User USD Million (2020-2025)
  • Table 377. Canada Oxytocic Pharmaceuticals, by Route of Administration USD Million (2020-2025)
  • Table 378. Canada Oxytocic Pharmaceuticals, by Indication USD Million (2020-2025)
  • Table 379. Canada Oxytocic Pharmaceuticals, by Source of Origin USD Million (2020-2025)
  • Table 380. Canada Oxytocic Pharmaceuticals, by End User USD Million (2020-2025)
  • Table 381. Mexico Oxytocic Pharmaceuticals, by Route of Administration USD Million (2020-2025)
  • Table 382. Mexico Oxytocic Pharmaceuticals, by Indication USD Million (2020-2025)
  • Table 383. Mexico Oxytocic Pharmaceuticals, by Source of Origin USD Million (2020-2025)
  • Table 384. Mexico Oxytocic Pharmaceuticals, by End User USD Million (2020-2025)
  • Table 385. Oxytocic Pharmaceuticals Sales: by Route of Administration(Litres)
  • Table 386. Oxytocic Pharmaceuticals Sales Intramuscular , by Region Litres (2020-2025)
  • Table 387. Oxytocic Pharmaceuticals Sales Intravenous Injection/Infusion , by Region Litres (2020-2025)
  • Table 388. Oxytocic Pharmaceuticals Sales: by Indication(Litres)
  • Table 389. Oxytocic Pharmaceuticals Sales Abortion Induced Incomplete , by Region Litres (2020-2025)
  • Table 390. Oxytocic Pharmaceuticals Sales Inevitable Abortion , by Region Litres (2020-2025)
  • Table 391. Oxytocic Pharmaceuticals Sales Postpartum Hemorrhage , by Region Litres (2020-2025)
  • Table 392. Oxytocic Pharmaceuticals Sales Labor Induction , by Region Litres (2020-2025)
  • Table 393. Oxytocic Pharmaceuticals Sales Labor Arrest , by Region Litres (2020-2025)
  • Table 394. Oxytocic Pharmaceuticals Sales: by Source of Origin(Litres)
  • Table 395. Oxytocic Pharmaceuticals Sales Natural Oxytocin (Animal Pituitary Extract) , by Region Litres (2020-2025)
  • Table 396. Oxytocic Pharmaceuticals Sales Synthetic Oxytocin Derivative , by Region Litres (2020-2025)
  • Table 397. Oxytocic Pharmaceuticals Sales: by End User(Litres)
  • Table 398. Oxytocic Pharmaceuticals Sales Hospitals , by Region Litres (2020-2025)
  • Table 399. Oxytocic Pharmaceuticals Sales Maternity Clinics , by Region Litres (2020-2025)
  • Table 400. Oxytocic Pharmaceuticals Sales Others , by Region Litres (2020-2025)
  • Table 401. South America Oxytocic Pharmaceuticals Sales, by Country Litres (2020-2025)
  • Table 402. South America Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2020-2025)
  • Table 403. South America Oxytocic Pharmaceuticals Sales, by Indication Litres (2020-2025)
  • Table 404. South America Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2020-2025)
  • Table 405. South America Oxytocic Pharmaceuticals Sales, by End User Litres (2020-2025)
  • Table 406. Brazil Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2020-2025)
  • Table 407. Brazil Oxytocic Pharmaceuticals Sales, by Indication Litres (2020-2025)
  • Table 408. Brazil Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2020-2025)
  • Table 409. Brazil Oxytocic Pharmaceuticals Sales, by End User Litres (2020-2025)
  • Table 410. Argentina Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2020-2025)
  • Table 411. Argentina Oxytocic Pharmaceuticals Sales, by Indication Litres (2020-2025)
  • Table 412. Argentina Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2020-2025)
  • Table 413. Argentina Oxytocic Pharmaceuticals Sales, by End User Litres (2020-2025)
  • Table 414. Rest of South America Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2020-2025)
  • Table 415. Rest of South America Oxytocic Pharmaceuticals Sales, by Indication Litres (2020-2025)
  • Table 416. Rest of South America Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2020-2025)
  • Table 417. Rest of South America Oxytocic Pharmaceuticals Sales, by End User Litres (2020-2025)
  • Table 418. Asia Pacific Oxytocic Pharmaceuticals Sales, by Country Litres (2020-2025)
  • Table 419. Asia Pacific Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2020-2025)
  • Table 420. Asia Pacific Oxytocic Pharmaceuticals Sales, by Indication Litres (2020-2025)
  • Table 421. Asia Pacific Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2020-2025)
  • Table 422. Asia Pacific Oxytocic Pharmaceuticals Sales, by End User Litres (2020-2025)
  • Table 423. China Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2020-2025)
  • Table 424. China Oxytocic Pharmaceuticals Sales, by Indication Litres (2020-2025)
  • Table 425. China Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2020-2025)
  • Table 426. China Oxytocic Pharmaceuticals Sales, by End User Litres (2020-2025)
  • Table 427. Japan Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2020-2025)
  • Table 428. Japan Oxytocic Pharmaceuticals Sales, by Indication Litres (2020-2025)
  • Table 429. Japan Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2020-2025)
  • Table 430. Japan Oxytocic Pharmaceuticals Sales, by End User Litres (2020-2025)
  • Table 431. India Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2020-2025)
  • Table 432. India Oxytocic Pharmaceuticals Sales, by Indication Litres (2020-2025)
  • Table 433. India Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2020-2025)
  • Table 434. India Oxytocic Pharmaceuticals Sales, by End User Litres (2020-2025)
  • Table 435. South Korea Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2020-2025)
  • Table 436. South Korea Oxytocic Pharmaceuticals Sales, by Indication Litres (2020-2025)
  • Table 437. South Korea Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2020-2025)
  • Table 438. South Korea Oxytocic Pharmaceuticals Sales, by End User Litres (2020-2025)
  • Table 439. Taiwan Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2020-2025)
  • Table 440. Taiwan Oxytocic Pharmaceuticals Sales, by Indication Litres (2020-2025)
  • Table 441. Taiwan Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2020-2025)
  • Table 442. Taiwan Oxytocic Pharmaceuticals Sales, by End User Litres (2020-2025)
  • Table 443. Australia Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2020-2025)
  • Table 444. Australia Oxytocic Pharmaceuticals Sales, by Indication Litres (2020-2025)
  • Table 445. Australia Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2020-2025)
  • Table 446. Australia Oxytocic Pharmaceuticals Sales, by End User Litres (2020-2025)
  • Table 447. Rest of Asia-Pacific Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2020-2025)
  • Table 448. Rest of Asia-Pacific Oxytocic Pharmaceuticals Sales, by Indication Litres (2020-2025)
  • Table 449. Rest of Asia-Pacific Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2020-2025)
  • Table 450. Rest of Asia-Pacific Oxytocic Pharmaceuticals Sales, by End User Litres (2020-2025)
  • Table 451. Europe Oxytocic Pharmaceuticals Sales, by Country Litres (2020-2025)
  • Table 452. Europe Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2020-2025)
  • Table 453. Europe Oxytocic Pharmaceuticals Sales, by Indication Litres (2020-2025)
  • Table 454. Europe Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2020-2025)
  • Table 455. Europe Oxytocic Pharmaceuticals Sales, by End User Litres (2020-2025)
  • Table 456. Germany Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2020-2025)
  • Table 457. Germany Oxytocic Pharmaceuticals Sales, by Indication Litres (2020-2025)
  • Table 458. Germany Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2020-2025)
  • Table 459. Germany Oxytocic Pharmaceuticals Sales, by End User Litres (2020-2025)
  • Table 460. France Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2020-2025)
  • Table 461. France Oxytocic Pharmaceuticals Sales, by Indication Litres (2020-2025)
  • Table 462. France Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2020-2025)
  • Table 463. France Oxytocic Pharmaceuticals Sales, by End User Litres (2020-2025)
  • Table 464. Italy Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2020-2025)
  • Table 465. Italy Oxytocic Pharmaceuticals Sales, by Indication Litres (2020-2025)
  • Table 466. Italy Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2020-2025)
  • Table 467. Italy Oxytocic Pharmaceuticals Sales, by End User Litres (2020-2025)
  • Table 468. United Kingdom Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2020-2025)
  • Table 469. United Kingdom Oxytocic Pharmaceuticals Sales, by Indication Litres (2020-2025)
  • Table 470. United Kingdom Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2020-2025)
  • Table 471. United Kingdom Oxytocic Pharmaceuticals Sales, by End User Litres (2020-2025)
  • Table 472. Netherlands Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2020-2025)
  • Table 473. Netherlands Oxytocic Pharmaceuticals Sales, by Indication Litres (2020-2025)
  • Table 474. Netherlands Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2020-2025)
  • Table 475. Netherlands Oxytocic Pharmaceuticals Sales, by End User Litres (2020-2025)
  • Table 476. Rest of Europe Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2020-2025)
  • Table 477. Rest of Europe Oxytocic Pharmaceuticals Sales, by Indication Litres (2020-2025)
  • Table 478. Rest of Europe Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2020-2025)
  • Table 479. Rest of Europe Oxytocic Pharmaceuticals Sales, by End User Litres (2020-2025)
  • Table 480. MEA Oxytocic Pharmaceuticals Sales, by Country Litres (2020-2025)
  • Table 481. MEA Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2020-2025)
  • Table 482. MEA Oxytocic Pharmaceuticals Sales, by Indication Litres (2020-2025)
  • Table 483. MEA Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2020-2025)
  • Table 484. MEA Oxytocic Pharmaceuticals Sales, by End User Litres (2020-2025)
  • Table 485. Middle East Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2020-2025)
  • Table 486. Middle East Oxytocic Pharmaceuticals Sales, by Indication Litres (2020-2025)
  • Table 487. Middle East Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2020-2025)
  • Table 488. Middle East Oxytocic Pharmaceuticals Sales, by End User Litres (2020-2025)
  • Table 489. Africa Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2020-2025)
  • Table 490. Africa Oxytocic Pharmaceuticals Sales, by Indication Litres (2020-2025)
  • Table 491. Africa Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2020-2025)
  • Table 492. Africa Oxytocic Pharmaceuticals Sales, by End User Litres (2020-2025)
  • Table 493. North America Oxytocic Pharmaceuticals Sales, by Country Litres (2020-2025)
  • Table 494. North America Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2020-2025)
  • Table 495. North America Oxytocic Pharmaceuticals Sales, by Indication Litres (2020-2025)
  • Table 496. North America Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2020-2025)
  • Table 497. North America Oxytocic Pharmaceuticals Sales, by End User Litres (2020-2025)
  • Table 498. United States Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2020-2025)
  • Table 499. United States Oxytocic Pharmaceuticals Sales, by Indication Litres (2020-2025)
  • Table 500. United States Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2020-2025)
  • Table 501. United States Oxytocic Pharmaceuticals Sales, by End User Litres (2020-2025)
  • Table 502. Canada Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2020-2025)
  • Table 503. Canada Oxytocic Pharmaceuticals Sales, by Indication Litres (2020-2025)
  • Table 504. Canada Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2020-2025)
  • Table 505. Canada Oxytocic Pharmaceuticals Sales, by End User Litres (2020-2025)
  • Table 506. Mexico Oxytocic Pharmaceuticals Sales, by Route of Administration Litres (2020-2025)
  • Table 507. Mexico Oxytocic Pharmaceuticals Sales, by Indication Litres (2020-2025)
  • Table 508. Mexico Oxytocic Pharmaceuticals Sales, by Source of Origin Litres (2020-2025)
  • Table 509. Mexico Oxytocic Pharmaceuticals Sales, by End User Litres (2020-2025)
  • Table 510. Research Programs/Design for This Report
  • Table 511. Key Data Information from Secondary Sources
  • Table 512. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Oxytocic Pharmaceuticals: by Route of Administration USD Million (2014-2019)
  • Figure 5. Global Oxytocic Pharmaceuticals: by Indication USD Million (2014-2019)
  • Figure 6. Global Oxytocic Pharmaceuticals: by Source of Origin USD Million (2014-2019)
  • Figure 7. Global Oxytocic Pharmaceuticals: by End User USD Million (2014-2019)
  • Figure 8. South America Oxytocic Pharmaceuticals Share (%), by Country
  • Figure 9. Asia Pacific Oxytocic Pharmaceuticals Share (%), by Country
  • Figure 10. Europe Oxytocic Pharmaceuticals Share (%), by Country
  • Figure 11. MEA Oxytocic Pharmaceuticals Share (%), by Country
  • Figure 12. North America Oxytocic Pharmaceuticals Share (%), by Country
  • Figure 13. Global Oxytocic Pharmaceuticals: by Route of Administration Litres (2014-2019)
  • Figure 14. Global Oxytocic Pharmaceuticals: by Indication Litres (2014-2019)
  • Figure 15. Global Oxytocic Pharmaceuticals: by Source of Origin Litres (2014-2019)
  • Figure 16. Global Oxytocic Pharmaceuticals: by End User Litres (2014-2019)
  • Figure 17. South America Oxytocic Pharmaceuticals Share (%), by Country
  • Figure 18. Asia Pacific Oxytocic Pharmaceuticals Share (%), by Country
  • Figure 19. Europe Oxytocic Pharmaceuticals Share (%), by Country
  • Figure 20. MEA Oxytocic Pharmaceuticals Share (%), by Country
  • Figure 21. North America Oxytocic Pharmaceuticals Share (%), by Country
  • Figure 22. Global Oxytocic Pharmaceuticals share by Players 2019 (%)
  • Figure 23. Global Oxytocic Pharmaceuticals share by Players (Top 3) 2019(%)
  • Figure 24. Global Oxytocic Pharmaceuticals share by Players (Top 5) 2019(%)
  • Figure 25. BCG Matrix for key Companies
  • Figure 26. Fresenius Kabi AG (Germany) Revenue, Net Income and Gross profit
  • Figure 27. Fresenius Kabi AG (Germany) Revenue: by Geography 2019
  • Figure 28. Baxter Healthcare Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 29. Baxter Healthcare Corporation (United States) Revenue: by Geography 2019
  • Figure 30. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Pfizer Inc. (United States) Revenue: by Geography 2019
  • Figure 32. Ferring Pharmaceuticals (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. Ferring Pharmaceuticals (Switzerland) Revenue: by Geography 2019
  • Figure 34. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 35. Novartis AG (Switzerland) Revenue: by Geography 2019
  • Figure 36. Teva Pharmaceutical Industries Ltd. ( Israel) Revenue, Net Income and Gross profit
  • Figure 37. Teva Pharmaceutical Industries Ltd. ( Israel) Revenue: by Geography 2019
  • Figure 38. APP Pharmaceuticals, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 39. APP Pharmaceuticals, LLC (United States) Revenue: by Geography 2019
  • Figure 40. LBS Labs (Belgium) Revenue, Net Income and Gross profit
  • Figure 41. LBS Labs (Belgium) Revenue: by Geography 2019
  • Figure 42. JHP Pharmaceuticals, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 43. JHP Pharmaceuticals, LLC (United States) Revenue: by Geography 2019
  • Figure 44. Global Oxytocic Pharmaceuticals: by Route of Administration USD Million (2020-2025)
  • Figure 45. Global Oxytocic Pharmaceuticals: by Indication USD Million (2020-2025)
  • Figure 46. Global Oxytocic Pharmaceuticals: by Source of Origin USD Million (2020-2025)
  • Figure 47. Global Oxytocic Pharmaceuticals: by End User USD Million (2020-2025)
  • Figure 48. South America Oxytocic Pharmaceuticals Share (%), by Country
  • Figure 49. Asia Pacific Oxytocic Pharmaceuticals Share (%), by Country
  • Figure 50. Europe Oxytocic Pharmaceuticals Share (%), by Country
  • Figure 51. MEA Oxytocic Pharmaceuticals Share (%), by Country
  • Figure 52. North America Oxytocic Pharmaceuticals Share (%), by Country
  • Figure 53. Global Oxytocic Pharmaceuticals: by Route of Administration Litres (2020-2025)
  • Figure 54. Global Oxytocic Pharmaceuticals: by Indication Litres (2020-2025)
  • Figure 55. Global Oxytocic Pharmaceuticals: by Source of Origin Litres (2020-2025)
  • Figure 56. Global Oxytocic Pharmaceuticals: by End User Litres (2020-2025)
  • Figure 57. South America Oxytocic Pharmaceuticals Share (%), by Country
  • Figure 58. Asia Pacific Oxytocic Pharmaceuticals Share (%), by Country
  • Figure 59. Europe Oxytocic Pharmaceuticals Share (%), by Country
  • Figure 60. MEA Oxytocic Pharmaceuticals Share (%), by Country
  • Figure 61. North America Oxytocic Pharmaceuticals Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Fresenius Kabi AG (Germany)
  • Baxter Healthcare Corporation (United States)
  • Pfizer Inc. (United States)
  • Ferring Pharmaceuticals (Switzerland)
  • Novartis AG (Switzerland)
  • Teva Pharmaceutical Industries Ltd. ( Israel)
  • APP Pharmaceuticals, LLC (United States)
  • LBS Labs (Belgium)
  • JHP Pharmaceuticals, LLC (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount
Slider
Slider
Slider
DOWNLOAD SAMPLE PDF

Speak with Analyst

Want to find out more about this report?

Get Free Consultation
Ask a Question!

Related Reports

Acemetacin Comprehensive Study by Application (Rheumatoid Arthritis, Osteoarthritis, Lower Back Pain, Postoperative Pain Reduction, Inflammation), End User (Hospitals, Pharmacy) Players and Region - ...
Acemetacin Comprehensive Study by Application (Rheumatoid Arthritis, Osteoarthritis, Lower Back Pain, Postoperative Pain Reduction, Inflammation), End User (Hospitals, Pharmacy) Players and Region - ...
$ 3800
Tuberculosis Vaccines Comprehensive Study by Type (Immunotherapeutic Vaccines, Booster Vaccines, Others), Application (Hospitals, Clinics, Others), Testing Type (Tuberculin Skin Test (TST), TB Blood ...
Tuberculosis Vaccines Comprehensive Study by Type (Immunotherapeutic Vaccines, Booster Vaccines, Others), Application (Hospitals, Clinics, Others), Testing Type (Tuberculin Skin Test (TST), TB Blood ...
$ 3800
Sulbactam Pivoxil Comprehensive Study by Application (Pharmaceutical, Research, Biosciences, Others), Form (Tablets, Powder, Suspension), Distribution Channel (Hospitals Pharmacies, Medical Stores, O...
Sulbactam Pivoxil Comprehensive Study by Application (Pharmaceutical, Research, Biosciences, Others), Form (Tablets, Powder, Suspension), Distribution Channel (Hospitals Pharmacies, Medical Stores, O...
$ 3800
Ofloxacin Comprehensive Study by Type (Oral, Intravenous Therapy (IV), Topical (Eye Drops & Ear Drops)), Application (Bronchitis, Pneumonia and Infections of the Skin, Reproductive Organs, Bladder, U...
Ofloxacin Comprehensive Study by Type (Oral, Intravenous Therapy (IV), Topical (Eye Drops & Ear Drops)), Application (Bronchitis, Pneumonia and Infections of the Skin, Reproductive Organs, Bladder, U...
$ 3800
Dental Anesthesia Comprehensive Study by Type (Local Anesthesia, General Anesthesia), Application (Hospital, Clinic, Other), Drugs (Lidocaine, Mepivacaine, Prilocaine, Bupivacaine), Mode Of Administr...
Dental Anesthesia Comprehensive Study by Type (Local Anesthesia, General Anesthesia), Application (Hospital, Clinic, Other), Drugs (Lidocaine, Mepivacaine, Prilocaine, Bupivacaine), Mode Of Administr...
$ 3800
Dalbavancin Comprehensive Study by Type (Intravenous Therapy, Oral Type), Application (Skin Infection, Soft Tissue Infection, Others), End Users (Hospitals and clinics, Chemical firms, API demanding ...
Dalbavancin Comprehensive Study by Type (Intravenous Therapy, Oral Type), Application (Skin Infection, Soft Tissue Infection, Others), End Users (Hospitals and clinics, Chemical firms, API demanding ...
$ 3800